Dr. Reddy’s Laboratories, Inc., a wholly owned subsidiary of Dr. Reddy’s Laboratories Ltd., has entered into a definitive agreement to acquire Mayne Pharma Group‘s U.S. generic prescription product portfolio for approximately $90 million upfront and contingent payments of up to $15 million.  The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including generic products focused on women’s health. For the financial ...